Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

Post by Cirruson Oct 23, 2015 9:06am
161 Views
Post# 24219770

Too much Headline Risk for me - switched to CXR

Too much Headline Risk for me - switched to CXRHere's me 2 cents - When research firms with questionable credentials can trim $20B off a high quality company like Valeant in one week, I have to conclude that the headline risks are not quantifiable.  I just can't comfortably estimate these headline risks in my financial model.  And then I can't sleep.

I'm concerned with US election candidates gearing up for next year, Valeant will continue to be a target for the forseeable future.  

I took a tax-loss yesterday on VRX and switched to CXR.  I think there's a lot more upside, with less headline risk.  

<< Previous
Bullboard Posts
Next >>